Table 2 Demographics of two groups of elderly patients with NSCLC treated with gefitinib 250 mg day−1 given in an EAP (Gridelli et al, 2003). Rerpoduced with permission.

From: Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations

Investigators

Gridelli et al (2003)

Soto Parra et al (2003)

Patients, n

18

41

Male : female, n

17 : 1

26 : 15

Median age (range) (years)

73.5 (70–80)

60 (38–69)

Disease stage, n

 

4

 IIIb

3

37

 IV

15

 

Eastern Cooperative Oncology Group performance status 1/2/3, n

4/11/3

All ⩾1

Tumour histology, n

  

 Squamous-cell carcinoma

10

8

 Adenocarcinoma

6

12

 Bronchioalveolar

1

0

 Undefined

1

11

Prior chemotherapy regimens, n

  

 0/1/⩾2

1/7/10

11/16/4

Back to article page